231 filings
Page 4 of 12
POS AM
g74ui 6nypproyy
13 Nov 20
Prospectus update (post-effective amendment)
5:03pm
8-K12G3
cf9h9769n3smnehc14g
13 Nov 20
Notification of registration of securities
7:05am
8-K
r25svgzp6lbslvztno1
13 Nov 20
Results of Operations and Financial Condition
7:03am
EFFECT
vm8m7oauo
13 Nov 20
Notice of effectiveness
12:15am
S-4/A
n5bdg
10 Nov 20
Registration of securities issued in business combination transactions (amended)
5:10pm
8-K
grgal l4eo5x1ga1p
10 Nov 20
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
7:02am
CORRESP
py2r0qr 2z7qwmuw
10 Nov 20
Correspondence with SEC
12:00am
8-K
7noihcj91syl2td01mw6
9 Nov 20
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
7:00am
8-K
dc2lke2tyh 0r0q13
29 Oct 20
Regulation FD Disclosure
4:03pm
8-K
vpltvkqpve
13 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease
7:01am
8-K
nv8xpm5
9 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
7:00am
8-K
9nmbqibvhn
8 Oct 20
Departure of Directors or Certain Officers
7:16am
UPLOAD
60r30x6mz1xfszc
8 Oct 20
Letter from SEC
12:00am
8-K
d0z2fd5e36x
6 Oct 20
Axovant Gene Therapies Announces Positive Six-month Follow-up Data from Second
7:14am
8-K
x253ty9xq
2 Oct 20
Other Events
5:19pm
424B5
h3rskmo
2 Oct 20
Prospectus supplement for primary offering
5:17pm
S-4
ix8r knykud
2 Oct 20
Registration of securities issued in business combination transactions
4:43pm
8-K
aly77r4 c2r
28 Sep 20
Submission of Matters to a Vote of Security Holders
4:56pm
DEFA14A
mitl etvv8wcdm04w
12 Aug 20
Additional proxy soliciting materials
4:06pm